Walleye Capital
MLTX icon

Walleye Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Walleye Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Sell
6,400
-400
-6% -$6.63K ﹤0.01% 3599
2025
Q4 		$89.6K Buy
+6,800
New +$80.2K ﹤0.01% 3911
2024
Q4 		– Sell
-3,200
Closed -$161K – 5273
2024
Q3 		$161K Buy
+3,200
New +$150K ﹤0.01% 4146

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's MLTX Position: Q1 2026 in Review

Walleye Capital increased its MoonLake Immunotherapeutics (MLTX) stake by 323% in Q1 2026, buying an estimated $4.05M and bringing the position to 320,472 shares worth $5.97M. The position accounts for 0.02% of the portfolio, ranked #695.

Walleye Capital first reported a position in MLTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $11.3M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Walleye Capital held 320,472 shares of MoonLake Immunotherapeutics worth $5.97M as of Q1 2026.
  • Walleye Capital bought 244,720 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $4.05M.
  • MoonLake Immunotherapeutics made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #695 holding.
  • Walleye Capital first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 7 quarters since.
  • Walleye Capital's MoonLake Immunotherapeutics position peaked at $11.3M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.